The company focuses on limiting tumor-autonomous growth and stimulating the immune system to attack the tumor by targeting the proteotoxic stress response/UPR to shut down cancer cell metabolism. Their TOBY program combines targeted chemotherapy with an immunooncology approach in a single small molecule.